![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Journal of Clinical Microbiology, February 2006, p. 586-588, Vol. 44, No. 2
0095-1137/06/$08.00+0 doi:10.1128/JCM.44.2.586-588.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Laboratory for Microbiology and Infection Control, Amphia Hospital, Breda, The Netherlands,1 Laboratory of Medical Microbiology, St. Elisabeth Hospital, Tilburg, The Netherlands2
Received 1 July 2005/ Returned for modification 23 August 2005/ Accepted 6 November 2005
 |
ABSTRACT |
|---|
 Top Abstract TextReferences |
|---|
|
TEXT |
|---|
|
TopAbstractTextReferences |
|---|
The purpose of this study is to evaluate the in vitro sensitivity and specificity of a recently developed medium called MRSA ID for the identification of MRSA using a well-defined collection of strains.
A collection consisting of 271 MRSA strains, 249 methicillin-susceptible Staphylococcus aureus (MSSA) strains, and 478 coagulase-negative staphylococci (CNS) was used. The collection was described previously (2, 3). In short, the MRSA isolates were collected in The Netherlands between 1989 and 1998 and are part of the MRSA strain collection of the National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands. Identification of strains as S. aureus and as being methicillin resistant was performed by duplex PCR for the mecA gene and the coagulase gene (11). Strains were selected on the basis of their different phage types (8, 13; J. A. Rost, unpublished data). The MSSA strains were isolated from cultures of blood collected between May 1996 and January 2005 from patients at the following five hospitals: St. Elisabeth Hospital and Tweesteden Hospital, Tilburg, The Netherlands; Pasteur Hospital, Oosterhout, The Netherlands; Tweesteden Hospital, Waalwijk, The Netherlands; and Amphia Hospital, Breda, The Netherlands. Only one isolate was included per patient per admission period. Isolates were identified by a latex agglutination test (Staphaurex Plus; Murex Diagnostics Ltd., Dartford, England), by the detection of free coagulase by the tube coagulase test with rabbit plasma, and by the detection of DNase (DNase agar; Oxoid Ltd., Basingstoke, England). If the results of these tests were discordant, an AccuProbe culture identification test (Gen-Probe, San Diego, Calif.) was performed according to the manufacturer's instructions, and this was considered the "gold standard." The blood culture isolates were classified as methicillin susceptible (MIC of oxacillin, 
2 µg/ml) at the time of collection by broth microdilution susceptibility testing performed according to CLSI (formerly NCCLS) standards (7). The isolates were stored at –70°C until they were tested.
MRSA ID is a new chromogenic medium for identification of MRSA in human specimens and was supplied as prepoured culture plates from bioMérieux, La Balme Les Grottes, France. The composition of the chromogenic and selective mix is proprietary. On MRSA ID, MRSA forms distinctive green colonies (Fig. 1). The selective mixture inhibits MSSA strains, most bacteria not belonging to the genus Staphylococcus, and yeasts. The isolates were inoculated onto Columbia agar plates with 5% sheep blood and incubated for 24 h at 35°C. From the resulting cultures, a suspension with a 0.5 McFarland standard was made, and subsequently, 10 µl was streaked onto an MRSA ID plate with a sterile loop using a three-streak dilution method. The results were read after 24 and 48 h of incubation at 35°C. Growth of colonies showing green coloration was considered to be positive (indicating MRSA). No growth or colonies with colors other than green were considered negative. The procedure was performed as recommended by the manufacturer.
|
The results obtained with MRSA ID are shown in Table 1. In the current evaluation, 29 MRSA strains gave discordant results, and a PCR for the mecA gene was performed on these isolates. A total of 20 (68%) of the MRSA strains had a negative result with the mecA PCR. These strains were removed from the analysis. The sensitivity of MRSA ID was 96.4% after 24 h and 98.8% after 48 h (P = 0.14). The specificity was 98.2% after 24 h and 89.7% after 48 h (P < 0.001). The sensitivity of MSA was statistically significant lower at both time intervals. The specificity of MSA was significantly lower at 24 h and lower but not statistically significant at 48 h (P = 0.09).
|
We evaluated the in vitro sensitivity and specificity of CHROMagar MRSA (CHROMagar Microbiology, Paris, France) using the same collection of strains (2). A total of 216 MRSA strains and 241 MSSA strains were tested. MRSA ID medium used in the present evaluation has a comparable sensitivity at both 24 and 48 h compared to CHROMagar MRSA medium (206/216 [95.4%] and 216/216 [100%] after 24 h and 48 h, respectively). The specificity of MRSA ID medium was significantly lower (P < 0.01), at both 24 and 48 h, than that of CHROMagar MRSA medium (0/241 [100%] at both 24 and 48 h). Overall, the accuracy of detection of MRSA at 24 h of incubation is comparable between MRSA ID and CHROMagar MRSA (18/500 and 10/457, respectively).
In another study, we evaluated the in vitro sensitivities and specificities of oxacillin resistance screening agar base (ORSAB; Oxoid Ltd.) and CHROMagar Staph aureus (CSA; CHROMagar Microbiology) (3). For screening of MRSA strains, antibiotic supplements were added to both media. The sensitivity was low after 24 h of incubation (CSA, 156/266 [58.6%]; ORSAB, 224/266 [84.2%]) but increased significantly after 48 h of incubation (CSA, 206/266 [77.5%]; ORSAB, 243/266 [91.4%]). The specificity for detection of MRSA (measured with MSSA) was high for both media after 24 h (CSA, 358/358 [100%]; ORSAB, 355/358 [99.2%]). After 48 h, it was lower for ORSAB (339/358 [94.7%]) but did not change for CSA. The MRSA ID medium used in the present evaluation has a significantly higher sensitivity than those determined for CSA and ORSAB at both 24 and 48 h in the previous study (P < 0.01). The specificity of MRSA ID is comparable to those determined for ORSAB and CSA at 24 h and significantly lower at 48 h (P < 0.001).
An important limitation of this study is that a high inoculum of MSSA and MRSA isolates in pure culture was used, in contrast to the low concentration usually present in clinical samples. This could lead to more false-negative results in a clinical evaluation, compared to our results. Also, the presence of species other than CNS was not evaluated. This may influence both sensitivity and specificity when MRSA ID medium is used on clinical samples.
In a recent evaluation by Reverdy et al. (10), MRSA ID was compared to ORSAB medium for the identification of MRSA using nasal swabs. Isolation of MRSA on Columbia CNA blood agar was used as the reference method. Suspected colonies were confirmed by mecA gene PCR. A total of 278 nasal swabs were inoculated, and 45 MRSA strains were isolated. After 24 h of incubation, 42 (93.3%) of the 45 strains were isolated on MRSA ID, and 38 (84.4%) were isolated on ORSAB medium. After 48 h, the sensitivity for both media reached 95.6%.
In a clinical evaluation, Perry et al. evaluated MRSA ID, CHROMagar MRSA, ORSAB, and selective mannitol broth for the detection of MRSA (9). A total of 747 swabs from various clinical sites were cultured. A total of 85 MRSA strains were isolated by a combination of all methods. After 48 h of incubation, 89%, 72%, and 78% of the MRSA strains were isolated on MRSA ID, CHROMagar MRSA, and ORSAB, respectively. There was little difference between CHROMagar MRSA, MRSA ID, and ORSAB for the isolation of MRSA from nasal swabs and axillae after 48 h of incubation. However, CHROMagar MRSA appeared to be inferior to all other media for the isolation of MRSA from perineal swabs, possibly due to the impact of the competing flora.
The current evaluation is different from local, clinical studies using consecutive clinical MRSA isolates in an endemic setting, where only a limited number of clonal types will be tested. This leads to an over- or underestimation of the true value of a test under evaluation in other settings. In the current study, a specific type is included only once and many different strains are tested. Therefore, this study provides results representative of a broad array of strains.
In conclusion, MRSA ID is sensitive and specific for differentiation between MSSA and MRSA in vitro. MRSA ID is able to detect a large number of different MRSA strains. The performance of MRSA ID was significantly better after 24 h than after 48 h of incubation. Therefore, with MRSA-ID, optimal results can be obtained within a day. Further clinical studies are required to determine the utility of MRSA ID for the detection of MRSA directly from clinical samples.
|
FOOTNOTES |
|---|
|
REFERENCES |
|---|
|
TopAbstractTextReferences |
|---|
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|
